US2018022741A1PendingUtilityA1
Compositions, formulations and methods for treating ocular diseases
Est. expiryMar 15, 2033(~6.6 yrs left)· nominal 20-yr term from priority
A61K 2039/505A61P 27/00A61K 31/538A61K 31/4439C07D 417/04A61K 31/426A61K 31/427C07D 277/64C07D 277/30A61K 31/428C07K 16/22A61K 2039/54A61K 31/506C07D 417/12A61K 31/496A61K 31/497A61K 31/513A61K 47/40A61K 38/179A61K 39/395A61K 47/26A61K 39/3955C07D 277/60A61K 9/0051C07D 277/56A61P 27/02A61K 31/433A61K 47/6951C07D 277/28A61K 9/0019
69
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.
Claims
exact text as granted — not AI-modified1 - 54 . (canceled)
55 . A method of treating a condition, the method comprising administering to a subject in need thereof:
a) a therapeutically-effective amount of a Tie-2 activator or a pharmaceutically-acceptable salt thereof; and b) a therapeutically-effective amount of an anti-VEGF binding agent.
56 . The method of claim 55 , wherein the Tie-2 activator binds a phosphatase.
57 . The method of claim 55 , wherein the Tie-2 activator inhibits a phosphatase.
58 . The method of claim 55 , wherein the therapeutically-effective amount of the Tie-2 activator is about 5 mg to about 60 mg.
59 . The method of claim 55 , wherein the therapeutically-effective amount of the Tie-2 activator is about 15 mg.
60 . The method of claim 55 , wherein the therapeutically-effective amount of the Tie-2 activator is about 30 mg.
61 . The method of claim 55 , wherein the therapeutically-effective amount of the anti-VEGF binding agent is about 0.5 mg to about 50 mg.
62 . The method of claim 55 , wherein the administration is intravitreal.
63 . The method of claim 55 , wherein the administration is subcutaneous.
64 . The method of claim 55 , wherein the subject is human.
65 . The method of claim 55 , wherein the condition is an ocular condition.
66 . The method of claim 55 , wherein the condition is diabetic macular edema.
67 . The method of claim 55 , wherein the condition is diabetic retinopathy.
68 . The method of claim 55 , wherein the condition is macular degeneration.
69 . The method of claim 55 , wherein the condition is vascular leak.
70 . The method of claim 55 , wherein the condition is glaucoma.
71 . The method of claim 55 , wherein the condition is cancer.
72 . A method of treating a condition, the method comprising administering to a subject in need thereof:
a) a therapeutically-effective amount of a HPTP-β binding agent or a pharmaceutically-acceptable salt thereof; and b) a therapeutically-effective amount of an anti-VEGF binding agent.
73 . The method of claim 72 , wherein the HPTP-β binding agent is an inhibitor of HPTP-β.
74 . The method of claim 72 , wherein the HPTP-β binding agent inhibits a phosphatase.
75 . The method of claim 72 , wherein the therapeutically-effective amount of the HPTP-β binding agent is about 5 mg to about 60 mg.
76 . The method of claim 72 , wherein the therapeutically-effective amount of the HPTP-β binding agent is about 15 mg.
77 . The method of claim 72 , wherein the therapeutically-effective amount of the HPTP-β binding agent is about 30 mg.
78 . The method of claim 72 , wherein the therapeutically-effective amount of the anti-VEGF binding agent is about 0.5 mg to about 50 mg.
79 . The method of claim 72 , wherein the administration is intravitreal.
80 . The method of claim 72 , wherein the administration is subcutaneous.
81 . The method of claim 72 , wherein the subject is human.
82 . The method of claim 72 , wherein the condition is an ocular condition.
83 . The method of claim 72 , wherein the condition is diabetic macular edema.
84 . The method of claim 72 , wherein the condition is diabetic retinopathy.
85 . The method of claim 72 , wherein the condition is macular degeneration.
86 . The method of claim 72 , wherein the condition is vascular leak.
87 . The method of claim 72 , wherein the condition is glaucoma.
88 . The method of claim 72 , wherein the condition is cancer.Join the waitlist — get patent alerts
Track US2018022741A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.